Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland. In 2018, Novavax received a US$89 million research grant from the Bill and Melinda Gates Foundation for development of vaccines for maternal immunization. The company’s first phase III trial, the 12,000 adult Resolve trial, for its respiratory syncytial virus vaccine, failed in September. This triggered an eighty-five percent dive in the company’s stock price.
About Novavax in brief
Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. As of 2020, it has an ongoing Phase III clinical trial in older adults for its candidate vaccine for seasonal influenza, NanoFlu and a candidate vaccine for prevention of COVID-19. In 2018, Novavax received a US$89 million research grant from the Bill and Melinda Gates Foundation for development of vaccines for maternal immunization.
The company’s first phase III trial, the 12,000 adult Resolve trial, for its respiratory syncytial virus vaccine, which would come to be known as ResVax, fail in September. This triggered an eighty-five percent dive in the company’s stock price. In 2019, late-stage clinical testing of ResVAX, failed for a second time, which resulted in a major downturn in investor confidence and a seventy percent reduction in capital value for the firm.
You want to know more about Novavax?
This page is based on the article Novavax published in Wikipedia (as of Jan. 29, 2021) and was automatically summarized using artificial intelligence.
